[go: up one dir, main page]

WO2005097421A9 - Methods for identifying risk of osteoarthritis and treatments thereof - Google Patents

Methods for identifying risk of osteoarthritis and treatments thereof Download PDF

Info

Publication number
WO2005097421A9
WO2005097421A9 PCT/US2005/010913 US2005010913W WO2005097421A9 WO 2005097421 A9 WO2005097421 A9 WO 2005097421A9 US 2005010913 W US2005010913 W US 2005010913W WO 2005097421 A9 WO2005097421 A9 WO 2005097421A9
Authority
WO
WIPO (PCT)
Prior art keywords
osteoarthritis
treatments
methods
identifying risk
identifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/010913
Other languages
French (fr)
Other versions
WO2005097421A2 (en
Inventor
Steven Mah
Andreas Braun
Stefan M. Kammerer
Matthew Roberts Nelson
Rikard Henry Reneland
Maria L. Langdown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequenom Inc
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Priority to EP05763391A priority Critical patent/EP1729930A2/en
Priority to CA002561669A priority patent/CA2561669A1/en
Publication of WO2005097421A2 publication Critical patent/WO2005097421A2/en
Anticipated expiration legal-status Critical
Publication of WO2005097421A9 publication Critical patent/WO2005097421A9/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/105Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/US2005/010913 2004-04-01 2005-03-31 Methods for identifying risk of osteoarthritis and treatments thereof Ceased WO2005097421A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05763391A EP1729930A2 (en) 2004-04-01 2005-03-31 Methods for identifying risk of osteoarthritis and treatments thereof
CA002561669A CA2561669A1 (en) 2004-04-01 2005-03-31 Methods for identifying risk of osteoarthritis and treatments thereof

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US55920304P 2004-04-01 2004-04-01
US55904004P 2004-04-01 2004-04-01
US55922504P 2004-04-01 2004-04-01
US55904204P 2004-04-01 2004-04-01
US55920204P 2004-04-01 2004-04-01
US55927504P 2004-04-01 2004-04-01
US55901104P 2004-04-01 2004-04-01
US60/559,042 2004-04-01
US60/559,202 2004-04-01
US60/559,275 2004-04-01
US60/559,203 2004-04-01
US60/559,040 2004-04-01
US60/559,225 2004-04-01
US60/559,011 2004-04-01

Publications (2)

Publication Number Publication Date
WO2005097421A2 WO2005097421A2 (en) 2005-10-20
WO2005097421A9 true WO2005097421A9 (en) 2010-01-14

Family

ID=35125645

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2005/010912 Ceased WO2005100604A2 (en) 2004-04-01 2005-03-31 Methods for identifying risk of osteoarthritis and treatments thereof
PCT/US2005/010913 Ceased WO2005097421A2 (en) 2004-04-01 2005-03-31 Methods for identifying risk of osteoarthritis and treatments thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2005/010912 Ceased WO2005100604A2 (en) 2004-04-01 2005-03-31 Methods for identifying risk of osteoarthritis and treatments thereof

Country Status (3)

Country Link
EP (2) EP1729930A2 (en)
CA (2) CA2561742A1 (en)
WO (2) WO2005100604A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
CN110372795A (en) 2007-08-02 2019-10-25 吉利德生物制剂公司 LOX and LOXL2 inhibitor and its application
WO2010071405A1 (en) * 2008-12-18 2010-06-24 Erasmus University Medical Center Rotterdam Markers for detecting predisposition for risk, incidence and progression of osteoarthritis
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
RU2012110585A (en) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. CATALYTIC DOMAINS OF LYSYLOXIDASE AND LOXL2
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
DK3456821T4 (en) 2017-09-19 2024-04-15 Deutsches Krebsforsch NON-INTEGRATING DNA VECTORS FOR GENETIC MODIFICATION OF CELLS
WO2019210080A1 (en) * 2018-04-25 2019-10-31 The Regents Of The University Of California Methods and compositions for skeletal and neurological disorders
CN112262213A (en) * 2018-06-20 2021-01-22 富尔玛株式会社 Novel anti-PAD 2 antibodies
EP3823989A2 (en) 2018-07-16 2021-05-26 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002366713A1 (en) * 2001-12-20 2003-07-09 Incyte Genomics, Inc. Nucleotide polymorphisms associated with osteoarthritis

Also Published As

Publication number Publication date
EP1756317A2 (en) 2007-02-28
EP1756317A4 (en) 2008-05-28
WO2005097421A2 (en) 2005-10-20
EP1729930A2 (en) 2006-12-13
CA2561669A1 (en) 2005-10-20
CA2561742A1 (en) 2005-10-27
WO2005100604A8 (en) 2006-03-09
WO2005100604A2 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
EP1835929B8 (en) Anti-kir combination treatments and methods
EP1740107A4 (en) Electromagnetic treatment apparatus and method
WO2005097421A9 (en) Methods for identifying risk of osteoarthritis and treatments thereof
AU2005316238B2 (en) Cancer treatment method
AU2004907262A0 (en) Methods of treatment
AU2004907263A0 (en) Methods of treatment
HK1115062A (en) Methods for the treatment of substance abuse and dependence
AU2004904399A0 (en) Method of treatment
AU2004905741A0 (en) Method of treatment
AU2004907137A0 (en) Method of treatment
AU2005902959A0 (en) Method of treatment
AU2005905222A0 (en) Method of treatment
AU2004907352A0 (en) Methods of treating pain
AU2004900546A0 (en) Method of Treatment and Composition
AU2005907121A0 (en) Micro-identifiers and methods of application thereof
HK1097275A (en) Compounds and methods for treatment of cancer
AU2004903941A0 (en) Methods and Compositions for the Treatment of Hypogammaglobulinemia
HK1121226A (en) Anbrosteeone derivatives and method of use thereof
AU2004900511A0 (en) Compositions and Methods of Treatment
AU2004904405A0 (en) Compositions and Methods of Treatment
AU2006901857A0 (en) Method of treatment and agents useful for same
AU2005902879A0 (en) Mortgage plan and method of implementation
AU2005906278A0 (en) Method of data processing and representation
HK1092700A (en) Compounds and methods of use
AU2005903854A0 (en) Compositions and methods of treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2561669

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005763391

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005763391

Country of ref document: EP